Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
- Registration Number
- NCT02452190
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Brief Summary
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 468
-
Written informed consent is obtained.
-
The participant is male or female, 12 years of age and older, with a diagnosis of asthma.
-
The participant has Forced Expiratory Volume in 1 Second (FEV1) reversibility according to standard American Thoracic Society (ATS) or European Respiratory Society (ERS) protocol.
-
The participant has required an inhaled corticosteroid.
-
The participant has required an additional asthma controller medication besides inhaled corticosteroids.
-
The participant has a history of asthma exacerbation.
-
The participant must be willing and able to comply with study restrictions, perform requisite procedures and remain at the clinic for the required duration during the study period, and be willing to return to the clinic for the follow-up evaluation as specified in this protocol.
- Additional criteria may apply, please contact the investigator for more information
-
The participant has any clinically significant, uncontrolled medical condition (treated or untreated) that would interfere with the study schedule or procedures, interpretation of efficacy results, or compromise the patient's safety.
-
The participant has another confounding underlying lung disorder
-
The participant has a known hypereosinophilic syndrome.
-
The participant has a diagnosis of malignancy within 5 years of the screening visit, except for treated and cured non-melanoma skin cancers.
-
The participant is a pregnant or lactating woman, or intends to become pregnant during the study. Any woman becoming pregnant during the study will be withdrawn from the study.
-
The participant is a current smoker or has a smoking history.
-
The participated in a clinical trial within 30 days or 5 half-lives of the investigational drug before screening, whichever is longer.
-
The participant was previously exposed to reslizumab.
-
The participant has a history of an immunodeficiency disorder including human immunodeficiency virus (HIV).
-
The participant has current or suspected drug and alcohol abuse.
-
The participant has an active helminthic parasitic infection or was treated for one within 6 months of screening.
-
The participant has a history of allergic reaction or hypersensitivity to any component of the study drug.
- Additional criteria may apply, please contact the investigator for more information
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Matching Placebo Reslizumab Reslizumab Reslizumab
- Primary Outcome Measures
Name Time Method Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment Day 1 to Week 52 A CAE was defined as a clinically-judged deterioration in asthma control, as determined by the investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention, including at least 1 of the following: 1) use of systemic corticosteroids (oral or injection) or at least a doubling from a stable maintenance oral corticosteroid dose for at least 3 days; 2) asthma-specific hospital admission; 3) asthma-specific emergency department visit. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors. Results are presented as adjusted means. For this analysis, the offset variable is calculated as the logarithm of treatment duration minus the summed duration of exacerbations during the treatment period.
- Secondary Outcome Measures
Name Time Method Change From Baseline to Week 52 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) Baseline, Week 52 Change in pre-bronchodilator FEV1 from baseline to week 52 is presented. FEV1 is a standard measurement of air movement in the lungs of participants with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.
Analysis of the change from baseline to each visit was performed using a mixed effect model for repeated measures (MMRM) including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.Change From Baseline to Week 52 in 6-item Asthma Control Questionnaire (ACQ-6) Score Baseline, Week 52 The ACQ-6 is a 6-item validated asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ-6 has a possible score ranges from 0 to 6, and the total score is the mean of all responses. The total score ranging from 0-6 (0=totally controlled and 6=severely uncontrolled). A higher score indicated poorer asthma control. Analysis of the change from baseline to each visit was performed using a mixed effect model for repeated measures (MMRM) including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Change From Baseline to Week 32 in St. George's Respiratory Questionnaire (SGRQ) Total Score Baseline, Week 32 The SGRQ is a 17-item questionnaire with 50 weighted responses. It provides a total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The total score and each of the SGRQ subscores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health. An increase in score indicates worsening health. Analysis of the change from baseline to each visit was performed using a mixed effect model for repeated measures (MMRM) including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Percentage of Asthma Control Days Day 1 to Week 52 The percentage of asthma control days over 52 weeks of treatment is presented. An asthma control day was defined as a day on which the participant used less than or equal to 2 puffs of inhaled short-acting beta-agonist, had no nighttime awakenings, and experienced no asthma exacerbations. Analysis of the change from baseline to each visit was performed using a mixed effect MMRM including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Kaplan-Meier (K-M) Estimate of Probability (Percent [%]) of Not Experiencing a CAE by Week 52 Day 1 to Week 52 CAE was defined as a clinically judged deterioration in asthma control, as determined by the investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention, including at least 1 of the following: 1) use of systemic corticosteroids (oral or injection) or at least a doubling from a stable maintenance oral corticosteroid dose for at least 3 days; 2) asthma-specific hospital admission; 3) asthma-specific emergency department visit.
The KM method was used to estimate and compare the distributions of time to first CAE between treatment groups. Participants without an event during the treatment period were censored at either the date of the end of treatment (Week 52) visit for participants who completed treatment or at the date of last dose (+4 weeks) for participants who discontinued early.Number of Moderate Exacerbations During 52 Weeks of Treatment Day 1 to Week 52 A moderate exacerbation was defined as a clinically judged deterioration in asthma control as determined by investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention requiring additional asthma controller medication that was not a systemic corticosteroid and did not result in an asthma-specific hospitalization or emergency department visit (that is, a medical intervention that did not otherwise meet the criteria for primary endpoint). Frequency of moderate exacerbations over 52-week treatment period is expressed as adjusted exacerbation rate in 52 weeks. Adjusted exacerbation rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors (age group, blood eosinophil group) and number of prior exacerbations, and an offset variable.
Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score Baseline, Week 52 AQLQ is a 32-item instrument administered as a self-assessment. AQLQ+12 is a modified version of AQLQ developed to measure functional impairments of participants aged 12-70 years. It is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Participants were asked to recall their experiences during the last 2 weeks and respond to each question on a 7-point scale (1=severe impairment, 7=no impairment), where higher scores indicated "better quality of life." Overall AQLQ+12 score is the mean of all 32 responses. Analysis of the change from baseline to each visit was performed using a MMRM including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Change From Baseline to Week 52 in Total Asthma Symptom Scores (Day and Night) Baseline, Week 52 Asthma symptoms were recorded by participant each day and night in an asthma control diary. Night score was assessed on a 5-point scale where 0=no symptoms, slept through night, to 4=bad night, no sleep. Day score was assessed on a 6-point scale where 0=very well, no symptoms, to 5= asthma very severe, unable to carry out daily activities. Total asthma symptom score was calculated by taking the sum of the night and day asthma symptom scores recorded, ranging from 0 (no symptom) to 9 (severe symptom). A lower symptom score indicated a better outcome. Analysis of the change from baseline to each visit was performed using a MMRM including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Number of CAEs Requiring Hospitalization and/or Emergency Department Visits During 52 Weeks of Treatment Day 1 to Week 52 A CAE was defined as a clinically judged deterioration in asthma control, as determined by the investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention, including at least 1 of the following: 1) use of systemic corticosteroids (oral or injection) or at least a doubling from a stable maintenance oral corticosteroid dose for at least 3 days; 2) asthma-specific hospital admission; 3) asthma-specific emergency department visit. The frequency of CAEs over 52-week treatment period is expressed as adjusted CAEs rate in 52 weeks. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors (age group, blood eosinophil group) and number of prior exacerbations, and an offset variable.
Trial Locations
- Locations (226)
Teva Investigational Site 13215
🇺🇸Bakersfield, California, United States
Teva Investigational Site 13235
🇺🇸Shiloh, Illinois, United States
Teva Investigational Site 13208
🇺🇸Tallahassee, Florida, United States
Teva Investigational Site 13181
🇺🇸Canoga Park, California, United States
Teva Investigational Site 13188
🇺🇸New Hyde Park, New York, United States
Teva Investigational Site 13259
🇺🇸Edmond, Oklahoma, United States
Teva Investigational Site 13247
🇺🇸Long Beach, California, United States
Teva Investigational Site 13251
🇺🇸Walnut Creek, California, United States
Teva Investigational Site 13254
🇺🇸Fresno, California, United States
Teva Investigational Site 13230
🇺🇸Chicago, Illinois, United States
Teva Investigational Site 54130
🇨🇿Jablonec nad Nisou, Czechia
Teva Investigational Site 11109
🇨🇦Windsor, Canada
Teva Investigational Site 32566
🇩🇪Hannover, Germany
Teva Investigational Site 13767
🇺🇸New York, New York, United States
Teva Investigational Site 13218
🇺🇸Jenkintown, Pennsylvania, United States
Teva Investigational Site 32556
🇩🇪Berlin, Germany
Teva Investigational Site 32565
🇩🇪Lubeck, Germany
Teva Investigational Site 32560
🇩🇪Frankfurt am Main, Germany
Teva Investigational Site 78084
🇦🇺Woolloongabba, Australia
Teva Investigational Site 11105
🇨🇦Etobicoke, Ontario, Canada
Teva Investigational Site 13185
🇺🇸Arlington, Texas, United States
Teva Investigational Site 78088
🇦🇺Parkville, Australia
Teva Investigational Site 13209
🇺🇸East Providence, Rhode Island, United States
Teva Investigational Site 78083
🇦🇺Nedlands, Australia
Teva Investigational Site 13257
🇺🇸Falls Church, Virginia, United States
Teva Investigational Site 32570
🇩🇪Berlin, Germany
Teva Investigational Site 78085
🇦🇺Bedford Park, Australia
Teva Investigational Site 13239
🇺🇸Richmond, Virginia, United States
Teva Investigational Site 32562
🇩🇪Hamburg, Germany
Teva Investigational Site 32551
🇩🇪Mainz, Germany
Teva Investigational Site 79047
🇳🇿Auckland, New Zealand
Teva Investigational Site 79046
🇳🇿Auckland, New Zealand
Teva Investigational Site 87014
🇰🇷Seoul, Korea, Republic of
Teva Investigational Site 87015
🇰🇷Bucheon, Korea, Republic of
Teva Investigational Site 90030
🇿🇦Durban, South Africa
Teva Investigational Site 31154
🇪🇸Vitoria-Gasteiz, Spain
Teva Investigational Site 90029
🇿🇦Cape Town, South Africa
Teva Investigational Site 58233
🇺🇦Vinnytsia, Ukraine
Teva Investigational Site 90026
🇿🇦Cape Town, South Africa
Teva Investigational Site 31149
🇪🇸Barcelona, Spain
Teva Investigational Site 90028
🇿🇦Bloemfontein, South Africa
Teva Investigational Site 82043
🇹🇷Mersin, Turkey
Teva Investigational Site 90032
🇿🇦Durban, South Africa
Teva Investigational Site 31152
🇪🇸Girona, Spain
Teva Investigational Site 13253
🇺🇸Cleveland, Ohio, United States
Teva Investigational Site 13186
🇺🇸Cincinnati, Ohio, United States
Teva Investigational Site 13224
🇺🇸San Antonio, Texas, United States
Teva Investigational Site 13205
🇺🇸Napa, California, United States
Teva Investigational Site 13764
🇺🇸San Jose, California, United States
Teva Investigational Site 13252
🇺🇸Stockton, California, United States
Teva Investigational Site 13256
🇺🇸Fort Lauderdale, Florida, United States
Teva Investigational Site 13243
🇺🇸Miami, Florida, United States
Teva Investigational Site 13249
🇺🇸Buford, Georgia, United States
Teva Investigational Site 13211
🇺🇸Normal, Illinois, United States
Teva Investigational Site 13202
🇺🇸Michigan City, Indiana, United States
Teva Investigational Site 13225
🇺🇸Lenexa, Kansas, United States
Teva Investigational Site 13222
🇺🇸Owensboro, Kentucky, United States
Teva Investigational Site 13204
🇺🇸Saint Louis, Missouri, United States
Teva Investigational Site 13258
🇺🇸Boys Town, Nebraska, United States
Teva Investigational Site 13183
🇺🇸Fairfax, Virginia, United States
Teva Investigational Site 13260
🇺🇸Dallas, Texas, United States
Teva Investigational Site 13184
🇺🇸Waco, Texas, United States
Teva Investigational Site 20032
🇦🇷Rosario, Argentina
Teva Investigational Site 78087
🇦🇺Sherwood, Australia
Teva Investigational Site 37055
🇧🇪Gent, Belgium
Teva Investigational Site 11106
🇨🇦Vancouver, British Columbia, Canada
Teva Investigational Site 32559
🇩🇪Bad Worishofen, Germany
Teva Investigational Site 54128
🇨🇿Jindrichuv Hradec, Czechia
Teva Investigational Site 54129
🇨🇿Tabor, Czechia
Teva Investigational Site 32561
🇩🇪Berlin, Germany
Teva Investigational Site 51216
ðŸ‡ðŸ‡ºBalassagyarmat, Hungary
Teva Investigational Site 51228
ðŸ‡ðŸ‡ºBudapest, Hungary
Teva Investigational Site 51231
ðŸ‡ðŸ‡ºKapuvar, Hungary
Teva Investigational Site 84047
🇯🇵Kodaira, Japan
Teva Investigational Site 87016
🇰🇷Seoul, Korea, Republic of
Teva Investigational Site 84032
🇯🇵Tokyo, Japan
Teva Investigational Site 53309
🇵🇱Tarnow, Poland
Teva Investigational Site 52111
🇷🇴Deva, Romania
Teva Investigational Site 90027
🇿🇦Benoni, South Africa
Teva Investigational Site 90031
🇿🇦Cape Town, South Africa
Teva Investigational Site 31147
🇪🇸Esplugues de Llobregat, Spain
Teva Investigational Site 82042
🇹🇷Ankara, Turkey
Teva Investigational Site 13212
🇺🇸Birmingham, Alabama, United States
Teva Investigational Site 13238
🇺🇸Oklahoma City, Oklahoma, United States
Teva Investigational Site 13194
🇺🇸Glendale, Arkansas, United States
Teva Investigational Site 13241
🇺🇸Flagstaff, Arizona, United States
Teva Investigational Site 13769
🇺🇸Belleville, New Jersey, United States
Teva Investigational Site 20033
🇦🇷Buenos Aires, Argentina
Teva Investigational Site 20053
🇦🇷Lanus, Argentina
Teva Investigational Site 20036
🇦🇷Mendoza, Argentina
Teva Investigational Site 51220
ðŸ‡ðŸ‡ºDebrecen, Hungary
Teva Investigational Site 51223
ðŸ‡ðŸ‡ºDebrecen, Hungary
Teva Investigational Site 13187
🇺🇸Provo, Utah, United States
Teva Investigational Site 13766
🇺🇸Waterbury, Connecticut, United States
Teva Investigational Site 13200
🇺🇸North Dartmouth, Massachusetts, United States
Teva Investigational Site 13226
🇺🇸Biloxi, Mississippi, United States
Teva Investigational Site 20040
🇦🇷Buenos Aires, Argentina
Teva Investigational Site 13223
🇺🇸Knoxville, Tennessee, United States
Teva Investigational Site 20037
🇦🇷Mar Del Plata, Argentina
Teva Investigational Site 51224
ðŸ‡ðŸ‡ºSzazhalombatta, Hungary
Teva Investigational Site 51219
ðŸ‡ðŸ‡ºSzeged, Hungary
Teva Investigational Site 13195
🇺🇸Medford, Oregon, United States
Teva Investigational Site 80081
🇮🇱Petah Tikva, Israel
Teva Investigational Site 13191
🇺🇸Lafayette, Louisiana, United States
Teva Investigational Site 20035
🇦🇷Buenos Aires, Argentina
Teva Investigational Site 13210
🇺🇸Ocean City, New Jersey, United States
Teva Investigational Site 20054
🇦🇷Rosario, Argentina
Teva Investigational Site 37053
🇧🇪Erpent, Belgium
Teva Investigational Site 51255
ðŸ‡ðŸ‡ºDombovar, Hungary
Teva Investigational Site 51222
ðŸ‡ðŸ‡ºGyor, Hungary
Teva Investigational Site 51227
ðŸ‡ðŸ‡ºHajdunanas, Hungary
Teva Investigational Site 20041
🇦🇷Cordoba, Argentina
Teva Investigational Site 20046
🇦🇷San Miguel de Tucuman, Argentina
Teva Investigational Site 51217
ðŸ‡ðŸ‡ºSzombathely, Hungary
Teva Investigational Site 20045
🇦🇷San Rafael, Argentina
Teva Investigational Site 37054
🇧🇪Bruxelles, Belgium
Teva Investigational Site 51221
ðŸ‡ðŸ‡ºCsorna, Hungary
Teva Investigational Site 80077
🇮🇱Ashkelon, Israel
Teva Investigational Site 80076
🇮🇱Haifa, Israel
Teva Investigational Site 80075
🇮🇱Rehovot, Israel
Teva Investigational Site 84036
🇯🇵Kanazawa-shi, Japan
Teva Investigational Site 51218
ðŸ‡ðŸ‡ºGodollo, Hungary
Teva Investigational Site 80078
🇮🇱Jerusalem, Israel
Teva Investigational Site 80080
🇮🇱Kfar Saba, Israel
Teva Investigational Site 84053
🇯🇵Ginowan, Japan
Teva Investigational Site 84049
🇯🇵Hakodate, Japan
Teva Investigational Site 84037
🇯🇵Kishiwada-shi, Japan
Teva Investigational Site 84044
🇯🇵Kobe, Japan
Teva Investigational Site 84041
🇯🇵Sagamihara, Japan
Teva Investigational Site 51226
ðŸ‡ðŸ‡ºKaposvar, Hungary
Teva Investigational Site 51225
ðŸ‡ðŸ‡ºSzigetvar, Hungary
Teva Investigational Site 51229
ðŸ‡ðŸ‡ºVeszprem, Hungary
Teva Investigational Site 84039
🇯🇵Amagasaki, Japan
Teva Investigational Site 84043
🇯🇵Mizunami-shi, Japan
Teva Investigational Site 84031
🇯🇵Tokyo, Japan
Teva Investigational Site 21088
🇲🇽Guadalajara, Mexico
Teva Investigational Site 21087
🇲🇽Monterrey, Mexico
Teva Investigational Site 21086
🇲🇽Zapopan, Mexico
Teva Investigational Site 50354
🇷🇺Kemerovo, Russian Federation
Teva Investigational Site 50349
🇷🇺Tomsk, Russian Federation
Teva Investigational Site 82041
🇹🇷Izmir, Turkey
Teva Investigational Site 58219
🇺🇦Dnipropetrovsk, Ukraine
Teva Investigational Site 58222
🇺🇦Ivano-Frankivsk, Ukraine
Teva Investigational Site 58213
🇺🇦Kharkiv, Ukraine
Teva Investigational Site 58214
🇺🇦Kremenchuk, Ukraine
Teva Investigational Site 58220
🇺🇦Kyiv, Ukraine
Teva Investigational Site 80094
🇮🇱Jerusalem, Israel
Teva Investigational Site 80073
🇮🇱Petach Tikva, Israel
Teva Investigational Site 84040
🇯🇵Yokohama-shi, Japan
Teva Investigational Site 84035
🇯🇵Toyoake-shi, Japan
Teva Investigational Site 80079
🇮🇱Ramat Gan, Israel
Teva Investigational Site 84048
🇯🇵Kobe, Japan
Teva Investigational Site 53315
🇵🇱Bialystok, Poland
Teva Investigational Site 53311
🇵🇱Krakow, Poland
Teva Investigational Site 53314
🇵🇱Lodz, Poland
Teva Investigational Site 84034
🇯🇵Hiroshima, Japan
Teva Investigational Site 84045
🇯🇵Kumamoto, Japan
Teva Investigational Site 21084
🇲🇽Guadalajara, Mexico
Teva Investigational Site 21085
🇲🇽Guadalajara, Mexico
Teva Investigational Site 53308
🇵🇱Gdansk, Poland
Teva Investigational Site 52110
🇷🇴Timisoara, Romania
Teva Investigational Site 50350
🇷🇺Barnaul, Russian Federation
Teva Investigational Site 82040
🇹🇷Kocaeli, Turkey
Teva Investigational Site 58216
🇺🇦Chernivtsi, Ukraine
Teva Investigational Site 58230
🇺🇦Kyiv, Ukraine
Teva Investigational Site 58226
🇺🇦Kyiv, Ukraine
Teva Investigational Site 58231
🇺🇦Zaporizhzhya, Ukraine
Teva Investigational Site 50351
🇷🇺Moscow, Russian Federation
Teva Investigational Site 84038
🇯🇵Toyama-shi, Japan
Teva Investigational Site 84046
🇯🇵Toyama, Japan
Teva Investigational Site 21089
🇲🇽Guadalajara, Mexico
Teva Investigational Site 53312
🇵🇱Lodz, Poland
Teva Investigational Site 52107
🇷🇴Bucharest, Romania
Teva Investigational Site 52104
🇷🇴Cluj-Napoca, Romania
Teva Investigational Site 53310
🇵🇱Bialystok, Poland
Teva Investigational Site 53313
🇵🇱Poznan, Poland
Teva Investigational Site 52108
🇷🇴Brasov, Romania
Teva Investigational Site 50355
🇷🇺Saint Petersburg, Russian Federation
Teva Investigational Site 58225
🇺🇦Dnipropetrovsk, Ukraine
Teva Investigational Site 58227
🇺🇦Kharkiv, Ukraine
Teva Investigational Site 58221
🇺🇦Kharkiv, Ukraine
Teva Investigational Site 58229
🇺🇦Vinnytsya, Ukraine
Teva Investigational Site 58224
🇺🇦Zhaporizhzhya, Ukraine
Teva Investigational Site 52109
🇷🇴Brasov, Romania
Teva Investigational Site 52105
🇷🇴Bucharest, Romania
Teva Investigational Site 52106
🇷🇴Targu Mures, Romania
Teva Investigational Site 50348
🇷🇺Moscow, Russian Federation
Teva Investigational Site 50347
🇷🇺Novosibirsk, Russian Federation
Teva Investigational Site 82039
🇹🇷Konya, Turkey
Teva Investigational Site 58223
🇺🇦Kharkiv, Ukraine
Teva Investigational Site 58228
🇺🇦Kryvyi Rih, Ukraine
Teva Investigational Site 58234
🇺🇦Sumy, Ukraine
Teva Investigational Site 50352
🇷🇺St. Petersburg, Russian Federation
Teva Investigational Site 58218
🇺🇦Kyiv, Ukraine
Teva Investigational Site 58253
🇺🇦Kyiv, Ukraine
Teva Investigational Site 35183
🇫🇷Toulouse, France
Teva Investigational Site 35182
🇫🇷Strasbourg, France
Teva Investigational Site 32568
🇩🇪Frankfurt, Germany
Teva Investigational Site 32563
🇩🇪Leipzig, Germany
Teva Investigational Site 32569
🇩🇪Witten, Germany
Teva Investigational Site 32555
🇩🇪Koblenz, Germany
Teva Investigational Site 32557
🇩🇪Leipzig, Germany
Teva Investigational Site 13216
🇺🇸Huntington Beach, California, United States
Teva Investigational Site 13203
🇺🇸Kissimmee, Florida, United States
Teva Investigational Site 13196
🇺🇸Aventura, Florida, United States
Teva Investigational Site 13197
🇺🇸Miami, Florida, United States
Teva Investigational Site 13246
🇺🇸Pembroke Pines, Florida, United States
Teva Investigational Site 13233
🇺🇸New Port Richey, Florida, United States
Teva Investigational Site 13765
🇺🇸Albany, Georgia, United States
Teva Investigational Site 13763
🇺🇸Lawrenceville, Georgia, United States
Teva Investigational Site 13232
🇺🇸New York, New York, United States
Teva Investigational Site 13189
🇺🇸Philadelphia, Pennsylvania, United States
Teva Investigational Site 13240
🇺🇸Toledo, Ohio, United States
Teva Investigational Site 13242
🇺🇸Bethlehem, Pennsylvania, United States
Teva Investigational Site 13190
🇺🇸Pittsburgh, Pennsylvania, United States
Teva Investigational Site 13217
🇺🇸Lincoln, Rhode Island, United States
Teva Investigational Site 13199
🇺🇸Corsicana, Texas, United States
Teva Investigational Site 13207
🇺🇸Abingdon, Virginia, United States
Teva Investigational Site 13220
🇺🇸Miami, Florida, United States
Teva Investigational Site 13229
🇺🇸Denver, Colorado, United States
Teva Investigational Site 13201
🇺🇸Orlando, Florida, United States
Teva Investigational Site 13250
🇺🇸Orlando, Florida, United States
Teva Investigational Site 13255
🇺🇸Tampa, Florida, United States
Teva Investigational Site 32567
🇩🇪Berlin, Germany
Teva Investigational Site 32564
🇩🇪Berlin, Germany
Teva Investigational Site 13227
🇺🇸Spokane, Washington, United States